|
|||||||||||||||||||||||||||||||||||||||||||||||
Analyst Conference Summaries |
|||||||||||||||||||||||||||||||||||||||||||||||
|
Recursion
|
2025 | |||
Recursion Q1 2025 |
Recursion Q2 2025 |
||
May 5, 2025 | August 5, 2025 |
Recursion (RXRX) is a clinical-stage biotechnology company specializing in using machine learning algoriths to discover potential new drug therapies. Lead candidates include REC-617 and REC-4881.
More Analyst Conference Pages:
AGEN |
AGIO |
ALLO |
ALNY |
AMAT |
AMGN |
APRE |
ARWR |
BIIB |
BLRX |
BMY |
BOLD |
CCCC |
CLDX |
CBIO |
BMY |
FATE |
GILD |
GLYC |
ILMN |
INO |
IONS |
LGND |
MCHP |
MRNA |
REGN |
RNA |
RXRX |
SAGE |
SANA |
SUPN |
VRTX |
VSTM |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2025 William P. Meyers